Protalix Biotherapeutics Inc (NYSEMKT:PLX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The brokerage presently has a $0.75 price target on the …
and will operate under leadership of PLX management team * Dipexium Pharmaceuticals Inc - co to issue about 36 million new shares of common stock to PLX stockholders under exchange ratio formula * Dipexium …
Reuters
Dipexium said it will issue about 36 million new shares of its stock to PLx shareholders, who will own just under 77% of outstanding shares while current Dipexium shareholders will own a little over 23%. The new company …
Houston-based PLX Pharma set its estimated IPO offering range on Friday, saying in a filing that it expects to sell 3,800,000 shares of its common stock at between $17.00 and $19.00 per share. The company's IPO is …
PLX Technology
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced the entry into a definitive exchange ... approximately 23.8 million shares of common stock, $0.001 par value per share (“Common Stock”). Concurrently, the Company …
Private
PLX Technology ... stock with its peers like VTSS stock and NVEC stock to see if the growth compares well with what can be expected for a company in that industry. Bottom line: The word bottom line comes because it is …
Mackie initiated coverage on shares of Protalix Biotherapeutics Inc (AMEX:PLX) in a research note released on Tuesday, StockTargetPrices.com reports. The firm issued a buy rating and a $1.00 price target on the stock. …
BNS1mon
Protalix BioTherapeutics, Inc.
Pluristem will own 35% of NewCo in return for its contribution of a perpetual license to commercialize PLX
With IDT offering $3.50 a share in cash, and IDT's share price closing at $5.58 on Friday, this deal should be worth $6.43 per share, yet PLX closed at a mere $3.99 on Friday. This represents an amazing 61% arbitrage …
PLX-R18 is Pluristem’s second cell therapy product in development ... Register now to create your own …
PLX Technology